151 related articles for article (PubMed ID: 30791601)
1. Characterisation of an Isogenic Model of Cisplatin Resistance in Oesophageal Adenocarcinoma Cells.
Buckley AM; Bibby BA; Dunne MR; Kennedy SA; Davern MB; Kennedy BN; Maher SG; O'Sullivan J
Pharmaceuticals (Basel); 2019 Feb; 12(1):. PubMed ID: 30791601
[TBL] [Abstract][Full Text] [Related]
2. Real-time metabolic profiling of oesophageal tumours reveals an altered metabolic phenotype to different oxygen tensions and to treatment with Pyrazinib.
Buckley AM; Dunne MR; Morrissey ME; Kennedy SA; Nolan A; Davern M; Foley EK; Clarke N; Lysaght J; Ravi N; O'Toole D; MacCarthy F; Reynolds JV; Kennedy BN; O'Sullivan J
Sci Rep; 2020 Jul; 10(1):12105. PubMed ID: 32694701
[TBL] [Abstract][Full Text] [Related]
3. Pyrazinib (P3), [(E)-2-(2-Pyrazin-2-yl-vinyl)-phenol], a small molecule pyrazine compound enhances radiosensitivity in oesophageal adenocarcinoma.
Buckley AM; Dunne MR; Lynam-Lennon N; Kennedy SA; Cannon A; Reynolds AL; Maher SG; Reynolds JV; Kennedy BN; O'Sullivan J
Cancer Lett; 2019 Apr; 447():115-129. PubMed ID: 30664962
[TBL] [Abstract][Full Text] [Related]
4. Alterations in DNA repair efficiency are involved in the radioresistance of esophageal adenocarcinoma.
Lynam-Lennon N; Reynolds JV; Pidgeon GP; Lysaght J; Marignol L; Maher SG
Radiat Res; 2010 Dec; 174(6):703-11. PubMed ID: 21128793
[TBL] [Abstract][Full Text] [Related]
5. Silencing microRNA-330-5p increases MMP1 expression and promotes an invasive phenotype in oesophageal adenocarcinoma.
Bibby BAS; Miranda CS; Reynolds JV; Cawthorne CJ; Maher SG
BMC Cancer; 2019 Aug; 19(1):784. PubMed ID: 31391080
[TBL] [Abstract][Full Text] [Related]
6. Altered mitochondrial function and energy metabolism is associated with a radioresistant phenotype in oesophageal adenocarcinoma.
Lynam-Lennon N; Maher SG; Maguire A; Phelan J; Muldoon C; Reynolds JV; O'Sullivan J
PLoS One; 2014; 9(6):e100738. PubMed ID: 24968221
[TBL] [Abstract][Full Text] [Related]
7. Leukaemia inhibitory factor is associated with treatment resistance in oesophageal adenocarcinoma.
Buckley AM; Lynam-Lennon N; Kennedy SA; Dunne MR; Aird JJ; Foley EK; Clarke N; Ravi N; O'Toole D; Reynolds JV; Kennedy BN; O'Sullivan J
Oncotarget; 2018 Sep; 9(72):33634-33647. PubMed ID: 30263091
[TBL] [Abstract][Full Text] [Related]
8. The role of Dickkopf-3 overexpression in esophageal adenocarcinoma.
Wang Z; Lin L; Thomas DG; Nadal E; Chang AC; Beer DG; Lin J
J Thorac Cardiovasc Surg; 2015 Aug; 150(2):377-385.e2. PubMed ID: 26093488
[TBL] [Abstract][Full Text] [Related]
9. Cross-resistance to cis-diamminedichloroplatinum(II) of a multidrug-resistant lymphoma cell line associated with decreased drug accumulation and enhanced DNA repair.
Chao CC
Eur J Pharmacol; 1996 Jun; 305(1-3):213-22. PubMed ID: 8813556
[TBL] [Abstract][Full Text] [Related]
10. Glycine-extended gastrin inhibits apoptosis in Barrett's oesophageal and oesophageal adenocarcinoma cells through JAK2/STAT3 activation.
Beales IL; Ogunwobi OO
J Mol Endocrinol; 2009 Apr; 42(4):305-18. PubMed ID: 19153190
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-330-5p as a Putative Modulator of Neoadjuvant Chemoradiotherapy Sensitivity in Oesophageal Adenocarcinoma.
Bibby BA; Reynolds JV; Maher SG
PLoS One; 2015; 10(7):e0134180. PubMed ID: 26221725
[TBL] [Abstract][Full Text] [Related]
12. Schedule-dependent reversion of cisplatin resistance by 5-fluorouracil in a cisplatin-resistant human lung adenocarcinoma cell line A549DDP.
Zhan M; Liu X
Chin Med J (Engl); 1999 Apr; 112(4):336-9. PubMed ID: 11593534
[TBL] [Abstract][Full Text] [Related]
13. Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance.
Yang L; Li N; Wang H; Jia X; Wang X; Luo J
Oncol Rep; 2012 Aug; 28(2):592-600. PubMed ID: 22614869
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of resistance to cis-diamminedichloroplatinum (II) in a rat ovarian carcinoma cell line.
Sekiya S; Oosaki T; Andoh S; Suzuki N; Akaboshi M; Takamizawa H
Eur J Cancer Clin Oncol; 1989 Mar; 25(3):429-37. PubMed ID: 2702997
[TBL] [Abstract][Full Text] [Related]
15. Molecular basis of cis-diamminedichloroplatinum(II) resistance: a review.
Chao CC
J Formos Med Assoc; 1996 Dec; 95(12):893-900. PubMed ID: 9000804
[TBL] [Abstract][Full Text] [Related]
16. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
Sharp SY; Rogers PM; Kelland LR
Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
[TBL] [Abstract][Full Text] [Related]
17. Identification and characterization of stemlike cells in human esophageal adenocarcinoma and normal epithelial cell lines.
Zhao R; Quaroni L; Casson AG
J Thorac Cardiovasc Surg; 2012 Nov; 144(5):1192-9. PubMed ID: 22980068
[TBL] [Abstract][Full Text] [Related]
18. X-ray and cis-diamminedichloroplatinum(II) cross-resistance in human tumor cell lines.
Schwartz JL; Rotmensch J; Beckett MA; Jaffe DR; Toohill M; Giovanazzi SM; McIntosh J; Weichselbaum RR
Cancer Res; 1988 Sep; 48(18):5133-5. PubMed ID: 3409240
[TBL] [Abstract][Full Text] [Related]
19. Resistance patterns between cis-diamminedichloroplatinum(II) and ionizing radiation.
De Pooter CM; Scalliet PG; Elst HJ; Huybrechts JJ; Gheuens EE; Van Oosterom AT; Fichtinger-Schepman AM; De Bruijn EA
Cancer Res; 1991 Sep; 51(17):4523-7. PubMed ID: 1873796
[TBL] [Abstract][Full Text] [Related]
20. Functional and transcriptomic characterization of cisplatin-resistant AGS and MKN-28 gastric cancer cell lines.
Mora-Lagos B; Cartas-Espinel I; Riquelme I; Parker AC; Piccolo SR; Viscarra T; Reyes ME; Zanella L; Buchegger K; Ili C; Brebi P
PLoS One; 2020; 15(1):e0228331. PubMed ID: 31990955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
